Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

While there continues to be a trickle of acquisitions — including AstraZeneca’s recent $1bn bid for EsoBiotec — big pharma has largely focused on licensing deals, often with Chinese biotechs. These ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...

Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.

AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

Multinational pharmaceutical company AstraZeneca plc has entered into a definitive agreement to acquire the Belgian biotech company EsoBiotec. This is reported in a press release from AstraZeneca. The ...

AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.

Cooley and Covington & Burling have scored roles in AstraZeneca's $1bn acquisition of Belgian cancer treatment company EsoBiotec. Covington is guiding AstraZeneca, marking the latest instance in a run ...

AstraZeneca (AZ) has announced that it will be expanding its cell therapy capabilities by acquiring EsoBiotec for up to $1bn.

AstraZeneca, a global, science-led biopharmaceutical company, has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...